Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT03102320 |
Date of registration:
|
30/03/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
ARCS-Multi |
Scientific title:
|
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies |
Date of first enrolment:
|
May 26, 2017 |
Target sample size:
|
173 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03102320 |
Study type:
|
Interventional |
Study design:
|
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 1
|
|
Countries of recruitment
|
Australia
|
Belgium
|
Canada
|
France
|
Germany
|
Italy
|
Korea, Republic of
|
Netherlands
|
Singapore
|
Spain
|
Switzerland
|
United Kingdom
|
United States
| | | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|